Skip to main content

tirofiban

Generic: TIROFIBAN HYDROCHLORIDE·Brand: AGGRASTAT, Aggrastat, TIROFIBAN HYDROCHLORIDE

tirofiban: sourced relationships with 1 company · 2 clinical trials tracked · 1 FDA decision.

tirofiban evidence translation

What we can confirm

1 FDA record · 2 tracked trials

What it means

Source-backed records connect tirofiban to NEXS; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could tirofiban → NEXS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Acute Ischemic Stroke

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
NEXUS BIOPHARMA INC (NEXS)
Reported 2023-02-07 · Current development: unknownSource
Approved
NEXUS BIOPHARMA INC (NEXS)
Reported 2023-02-07 · Current development: unknownSource
Approved
Clinical Trial Registry Records (2)

Safety and Efficacy of Adjunct Tirofiban Treatment After Successful Mechanical Thrombectomy Recanalization in Acute Anterior Circulation Ischemic Stroke- A Multicenter, Prospective, Double-blind, Randomized Trial

NCT06265051Registry updated 2026-03-11·Phase 2/Phase 3
Completed

Primary endpoint: Proportion of patients functionally independent (mRS score 0 to 2) at 90 days

InterventionalRandomizedquadruple1,380 enrolledStarted 2024-04Completion 2025-121 site · ChinaXiang Luo

Randomized Multi-center Clinical Trial to Assess Effectiveness and Safety of Tirofiban Versus Intravenous Aspirin in Patients With Acute Ischemic Stroke Secondary to Tandem Injury, Subject to Recanalization Therapy Through Endovascular Treatment

NCT05225961Registry updated 2026-02-18·Phase 4
Active, not recruiting

Primary endpoint: Carotid Reocclusion

InterventionalRandomizedsingle240 targetStarted 2022-05Completion 2026-0613 sites · SpainFundación Pública Andaluza para la gestión de la Investigación en Sevilla
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE Tirofiban Hydrochloride Injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Tirofiban Hydrochloride Injection is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory is(NEXS)FDA ↗
ANDA213947UNKNOWNStandardIntravenousSolution

Frequently asked questions

Which companies have sourced relationships with tirofiban?

tirofiban has dated SEC/FDA relationship records for NEXUS BIOPHARMA INC.

How many clinical trials involve tirofiban?

BioSniper tracks 2 clinical trials involving tirofiban.

What is tirofiban's latest FDA decision?

The most recent tracked FDA decision for tirofiban is Approval for 1 INDICATIONS AND USAGE Tirofiban Hydrochloride Injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Tirofiban Hydrochloride Injection is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory is, dated February 7, 2023.